BillionToOne (BLLN) vs Veracyte (VCYT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BillionToOne is the larger company by market cap ($4.63 billion vs $3.64 billion), about 1.3 times the size. On valuation, Veracyte trades at a lower forward P/E (23.2x vs 66.1x for BillionToOne). Veracyte converts more of its revenue into profit, with a net margin of 12.8% versus 2.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLLN | VCYT |
|---|---|---|
| Share price | $98.09 | $45.23 |
| Market cap | $4.63B | $3.64B |
| 1-day change | +2.81% | +3.74% |
| YTD return | +19.86% | +7.43% |
| 1-year return | — | +29.49% |
| 5-year return | — | +0.16% |
| P/E ratio (TTM) | 155.70 | 31.19 |
| Forward P/E | 66.05 | 23.25 |
| EPS (TTM) | $0.63 | $1.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $305.11M | $517.14M |
| Revenue growth (YoY) | +99.97% | +16.01% |
| Net income (latest FY) | $7.45M | $66.35M |
| Gross margin | 68.32% | 70.10% |
| Operating margin | 5.25% | 11.17% |
| Net margin | 2.44% | 12.83% |
| 52-week high | $150.44 | $60.91 |
| 52-week low | $61.96 | $29.46 |
| Distance from 52-week high | -34.80% | -25.74% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +31.51% | +29.16% |
| Average volume | 689.14K | 1.36M |
| Shares outstanding | 42.64M | 80.39M |
| Employees | 713 | 755 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BillionToOne trades at a higher earnings multiple (155.7x vs 31.2x trailing P/E).
- Veracyte is more profitable, keeping 12.8 cents of every revenue dollar as net income versus 2.4 cents for BillionToOne.
- BillionToOne grew revenue faster in its latest fiscal year (+99.97% vs +16.01%).
About BillionToOne
BLLN stock →BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection.
Health Care · Medical Specialities · 713 employees
About Veracyte
VCYT stock →Veracyte, Inc. operates as a diagnostics company in the United States and internationally.
Health Care · Medical Specialities · 755 employees
BLLN vs VCYT FAQ
Which is bigger, BillionToOne or Veracyte?
BillionToOne (BLLN) is larger, with a market capitalization of $4.63B compared with $3.64B for Veracyte (VCYT).
Which has the lower P/E ratio, BLLN or VCYT?
VCYT has the lower trailing P/E at 31.2, versus 155.7 for BLLN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are BillionToOne and Veracyte in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.